Short-Term Continuous Subcutaneous Insulin Infusion Treatment In Newly Diagnosed Type 2 Diabetes: A Systematic Review

Objective To evaluate the efficacy and safety of short-term continuous subcutaneous insulin infusion treatment in newly diagnosed type 2 diabetes.Methods We electronically searched PubMed, EMbase, The Cochrane Library(issue 2, 2007), The National Research Register, CBM, CNKI and VIP.We also handsearched Chinese Journal of Endocrinology and Metabolism, Chinese Journal of Diabetes and Journal of Practical Diabetology. Randomized controlled trials of clinical therapeutic studies on continuous subcutaneous insulin infusion treatment in newly diagnosed type 2 diabetes were included. The quality of included studies was evaluated and Meta-analysis was performed.Results Ten trials involving 725 participants were included. Meta-analysis indicated that CSII was more effective than MSII in improving blood glucose of newly diagnosed type 2 diabetes. FPG[ WMD -0.47, 95%CI(-0.60, -0.33) ], PPG[ WMD -0.31, 95%CI(-0.44, -0.18) ].To reach the target blood glucose level, the average duration of treatment[ WMD -5.62, 95%CI(-7.71, -3.52) ], the daily insulin dose[ WMD -9.58, 95%CI(-12.15, -7.02) ] and the hypoglycemia incidence[RR 0.22, 95%CI(0.13, 0.39) ] were decreased in CSII group compared with MSII group.Conclusion Compared with MSII, CSII is more effective and safer for newly diagnosed type 2 diabetes.